M itochondria comprise the intracellular energy source of cells. Because the brain is a high-metabolism organ, mitochondria play a central role in cerebral physiology and pathophysiology. During injury or disease, mitochondria may be a key regulator for neurodegeneration, as well as neurorecovery, depending on its functionality.
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Care and Use of Laboratory Animals. Adult male Sprague-Dawley rats (320-350 g, Charles River Laboratories) were used under isoflurane anesthesia (1.5% in 30%/70% oxygen/nitrous gas mix). After standard procedures, SAH was performed by introducing a 3-0 prolene monofilament suture from the external carotid artery into the internal carotid artery and advancing it until resistance was experienced at the bifurcation of the internal carotid artery into the anterior and middle cerebral arteries. At this time, the suture was further advanced 5 mm to puncture the artery, and then it was quickly withdrawn. Sham-operated controls received the same procedure without inserting the filament. Animals were recovered for 24 hours, and then all rats were assessed with the standard 5-point neuroscore scale to evaluate neurological outcomes.
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CSF (at least 50 µL per rat) was collected from the cisterna magna for JC1 analysis (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanineiodide). Six rats were used for sham-operated group, and 24 rats were subjected to SAH. Overall, 64% (9 of 14) or 40% (4 of 10) of rats survived at 24 hours or at 72 hours after SAH surgery, respectively. The relatively high mortality rates reflect the severity of this rat model, and these models did not receive rigorous medical care in an intensive care unit unlike patients with SAH (see below).
SAH Subject Recruitment and Sample Collection
Consecutive patients within 96 hours of onset of spontaneous, nontraumatic SAH were prospectively enrolled into a large SAH biomarker cohort study, and serial blood and available CSF were collected and stored. CSF samples were collected only if patient has an external ventricular drain placed for clinical indications.
Patients with traumatic SAH, pregnancy, end-stage renal or hepatic disease, intracranial malignancies, or infectious meningitis were excluded. Control subjects were patients undergoing trial of CSF diversion for evaluation of possible normal pressure hydrocephalus. All subjects were enrolled after informed consent and in accordance with institutional review board approved protocols. In both subject populations, serial CSF, serum, and plasma samples were immediately processed after collection. Samples were centrifuged at room temperature at 3900 rpm for 15 minutes, and supinate was aliquoted and immediately frozen on dry ice and stored at −80°C until analysis.
Clinical Variables and Outcome Assessment
Angiographic vasospasm was defined as >50% reduction in diameter of any intracerebral vessel on digital subtraction cerebral angiography on post-SAH days 6 to 8 compared with baseline. Per institutional clinical protocol, all patients with SAH underwent digital subtraction cerebral angiography upon initial presentation and then again on post-SAH days 6 to 8 for evaluation of angiographic vasospasm. When multiple vessels were involved, vasospasm status was classified based on the most severely affected vessel. Long-term functional outcomes were prospectively assessed at 3-month intervals using modified Rankin Scale via standardized telephone interview. A standardized script was used to perform modified Rankin scoring to reduce interrater variability. Poor outcome was defined as modified Rankin Scale >2.
Electron Microscopy Analysis
After centrifugation at 14 000 rpm for 20 minutes, pellets obtained from CSF samples were fixed in 2.0% glutaraldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.4 (Electron Microscopy Sciences) for 1 hour at room temperature on a rocker. They were rinsed in cacodylate buffer, gently scraped and pelleted, and post-fixed in 1.0% osmium tetroxide in cacodylate buffer for 1 hour on ice. They were rinsed in buffer and stabilized with a small amount of 2% agarose in PBS to hold them together. They were then dehydrated through a graded series of ethanol to 100%, followed by propylene oxide, 100%. They were infiltrated with Epon resin (Ted Pella) in a 1:1 solution of Epon:propylene oxide overnight on a rocker at room temperature. The next day, they were placed in fresh Epon for several hours and then embedded in Epon overnight at 60°C. Thin sections were cut on a Leica EM UC7 ultramicrotome, collected on formvar-coated grids, stained with uranyl acetate and lead citrate, and examined in a JEOL JEM 1011 transmission electron microscope at 80 kV. Images were collected using an AMT digital imaging system (Advanced Microscopy Techniques).
Western Blot Analysis
Western blot was performed as previously reported. 12 Each sample was loaded onto 4% to 20% Tris-glycine gels. After electrophoresis and transferring to nitrocellulose membranes, the membranes were blocked in Tris-buffered saline containing 0.1% Tween 20 and 0.2% I-block (Tropix) for 90 minutes at room temperature. Membranes were then incubated overnight at 4°C with following primary antibodies: anti-TOM40 (1:200, Santacruz) and anti-ANT1 antibody (1:200, Abcam). After incubation with peroxidase-conjugated secondary antibodies, visualization was enhanced by chemiluminescence (GE Healthcare).
Fluorescence-Activated Cell Sorter Analysis
Standard fluorescence-activated cell sorter analysis was performed by BD Fortessa as described before. 10 To label mitochondria, MitoTracker Figure 1 . Extracellular mitochondrial functional assay in a rat subarachnoid hemorrhage (SAH) model in vivo. Rats were subjected to SAH by endovascular perforation, and cerebrospinal fluid (CSF) samples were collected at 24 and 72 h after SAH onset. JC1 green or JC1 red indicates collapsed mitochondria or intact mitochondria, respectively. A, CSF JC1 value at 24 h after SAH was lower than sham-operated group. Then, JC1 value was slightly recovered at 72 h after SAH. Sham; n=6, SAH 24 hours; n=9, SAH 72 hours; n=4. *P<0.05, **P<0.01 vs sham. B, Neuroscore was significantly higher at 24 h after SAH compared with sham-operated group. **P<0.01. C, Regression analysis demonstrated that JC1 ratio was inversely correlated with neuroscore after SAH. Note: lower CSF volumes collected from the rat SAH models preclude the use of fluorescence-activated cell sorter to perform true particle quantification (see human data in Figure 2 below). JCI indicates 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanineiodide. 
Mitochondria Membrane Potential Measurement
Each rat CSF sample (100 µL; rat CSF 25 µL was diluted with 75 µL PBS) or human CSF sample (100 µL) was incubated with JC1 (2 μL of 50 μmol/L in 50% dimethyl sulfoxide) for 20 minutes at 37°C in 96-well Microfluor 1 plate (Thermo Fisher Scientific). JC1 dye exhibits potential-dependent accumulation in mitochondria, indicated by fluorescence emission shift from green (Ex 485 nm/Em 516 nm) to red (Ex 570 nm/Em 590 nm). Background fluorescent signal from each sample (100 μL containing 2 μL of 50% dimethyl sulfoxide) was subtracted from JC1 fluorescent value, and mitochondria membrane potential was determined by the red/green fluorescent ratio after top-read measurement in SpectraMax M5 microplate reader.
Statistical Methods
All of experiments were performed with full blinding, allocation concealment, and randomization. Continuous variables were compared using Student t or Wilcoxon rank-sum test depending on data distribution normality. Depending on data normality, Pearson or Spearman correlation was used to measure strength of association between continuous variables. Multiple comparisons were evaluated by 1-way ANOVA followed by Kruskal-Wallis test. All statistical analyses were performed using JMP Pro 12.1.0.
Results
JC1 Mitochondrial Membrane Potential in Rat CSF After SAH
To assess extracellular mitochondria in vivo, we collected rat CSF at 24 and 72 hours after SAH. Extracellular mitochondria were assessed with the standard JC1 assay ( Figure  I in the online-only Data Supplement). JC1 green fluorescence (presumably reflecting mitochondria with collapsed membrane potentials) was significantly increased at 24 and 72 hours after SAH, and JC1 red fluorescence (presumably reflecting mitochondria with intact membrane potentials) was increased at 72 hours after SAH ( Figure 1A ). Because total fluorescence signals may be correlated with mitochondrial density, these findings indirectly suggest that mitochondrial particle numbers in CSF may be elevated in these rat models of SAH. Next, we calculated the ratio of red-to-green JC1 signal, which is generally thought to reflect mitochondrial integrity (ie, the overall status of mitochondria with preserved membrane potentials). Compared with the shamoperated group, these JC1 ratio levels were lower at 24 hours after SAH, and then JC1 ratios were slightly recovered at 72 hours, indicating the functional shift of mitochondria in the CSF ( Figure 1A ). As expected, neuroscore measurements were elevated at 24 hours after SAH, consistent with neurological deficits ( Figure 1B) . A regression analysis suggested that SAH-induced neurological deficits were inversely correlated with JC1 red-to-green ratios in the CSF ( Figure 1C ). (Figure 2A ) and mitochondrial proteins ( Figure 2B ) in CSF samples. We performed flow cytometry for all mitochondrial particles labeled with MitoTracker Deep Red FM, and the analysis revealed an increase in CSF extracellular mitochondrial particles after SAH ( Figure 2C ).
Mitochondrial Membrane Potential in CSF and Outcomes After SAH
Next, we asked whether mitochondrial membrane potential could be detected in these CSF samples. Interestingly, mitochondrial membrane potential was significantly lower in SAH subjects compared with controls ( Figure 3A ). There were no differences in size distribution and the percentage of mitochondria among all particles between good versus poor outcomes after SAH ( Figure 3B ). However, there appeared to be an inverse relationship between membrane potential (JC1 red-to-green ratio) and brain injury severity. Subjects with higher SAH clinical severity as measured by Hunt and Hess score had lower CSF JC1 ratio levels on day 1 ( Figure 3C ). Furthermore, recovery of JC1 ratio levels on day 3 was significantly associated with good outcomes at 3 months after SAH ( Figure 3D ).
One potential confound is that CSF mitochondrial measurements in SAH may be contaminated by blood. If so, one would expect that CSF after SAH would have higher JC1 ratios than controls. The opposite was true here, with lower JC1 ratio levels in SAH cases. When mitochondrial membrane potentials were measured in plasma samples from the same patients, mitochondrial membrane potential was significantly lower in SAH subjects compared with controls ( Figure 4A) , and there was no correlation between blood JC1 levels and functional outcome ( Figure 4B) , again suggesting that these responses in CSF may not be driven by blood contamination after SAH.
Finally, we explored the potential cellular origin of these CSF mitochondria signals found in SAH. Because extracellular mitochondria tend to be contained within membranous particles, cell-specific markers embedded in these membranes may provide indirect information on potential cellular origins. We performed flow cytometry for all functional mitochondria particles labeled with MitoTracker Red CMXRos and assessed positive events for vWF (endothelial cell origin), GLAST (astrocyte), CD45 (microglia/macrophage), and CD41/CD61 (platelet; Figure 5A ). Subjects with good outcomes at 3 month had a significantly higher percentage of GLAST-positive mitochondria particles in their CSF at day 3 after SAH ( Figure 5B ), but there was no correlation with other cellular origin markers ( Figure 5C ), suggesting that the differences in CSF mitochondrial membrane potential observed between the good and the poor outcome groups may be driven by mitochondria linked to astrocytic origin. 
Discussion
Taken together, we found that (1) extracellular mitochondrial membrane potentials were reduced in rat CSF after SAH, (2) reductions in mitochondria membrane potentials were also detectable in human CSF after SAH, (3) higher mitochondrial membrane potentials in CSF were associated with good 3-month outcomes after SAH, and (4) a higher proportion of mitochondria that were associated with good 3-month outcomes may be potentially linked to astrocytic origins.
In both rat models and human patients, extracellular mitochondrial function was detectable in normal CSF, and JC1 ratios were decreased after SAH. Therefore, assessment of mitochondrial function in CSF may provide an indirect way to assess brain injury; lower CSF mitochondrial membrane potentials may indicate damaged brain, whereas higher CSF membrane potentials may indicate metabolic recovery. But there are several important caveats. First, it is unclear whether CSF mitochondria particles represent some type of active release or merely reflect passive release or even debris from compromised cells. The fact that mitochondrial membrane potential was measurable and higher in control CSF than in SAH, and higher CSF membrane potentials were associated with better SAH outcomes, might argue against the worry that CSF mitochondrial particles simply represent uninformative debris. Further studies are required to investigate mitochondrial trafficking mechanisms in injured human brain. Second, JC1 values may be affected by the dye concentrations used. It is known that a high concentration of JC1 may produce nonspecific dye aggregation giving a potentially imperfect indication of mitochondrial membrane potential. Before these studies, we tried to optimize JC1 dye concentrations for our model systems ( Figure I in the online-only Data Supplement), but future experiments testing other mitochondria dyes (eg, TMRE [tetramethylrhodamine, ethyl ester]) may be useful. Third, it should be noted that our initial human data are relatively limited and control subjects, while they have no acute brain injury, may not be completely healthy because they comprise patients suspected of having normal pressure hydrocephalus. Fourth, we do not know why CSF mitochondrial membrane potentials in the early stages of SAH can predict later outcomes. Nevertheless, our findings may be consistent with the recent idea of early brain injury as the key pathological mechanism in SAH. 13 This phenomenon begins immediately after cerebral hemorrhage and is known to trigger cell death along with mitochondrial dysfunction.
14 Our CSF mitochondrial membrane potential measurements at day 1 after SAH showed significant reduction compared with controls, and recovery in these values at day 3 seems to correspond with patient outcomes. Hence, extracellular mitochondria in CSF may be a candidate biomarker that connects early brain injury mechanisms with recovery after SAH. Whether and how extracellular mitochondria may mechanistically connect to delayed vascular sequelae of SAH (vasospasm, perturbations in hemostasis and fibrinolysis, cerebral ischemia, etc) 15, 16 remain to be determined. Fifth, mitochondria are highly dynamic entities with highly responsive profiles of fission and 
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fusion. 3 How mitochondrial dynamics may affect our extracellular hypothesis requires further consideration. A sixth caveat relates to blood contamination in CSF. The lack of correlation between blood mitochondrial levels and CSF levels suggests that this might not be a major concern. However, a fraction of all CSF mitochondria was still positive for platelet markers suggesting blood origins. 17 If so, then patients with more subarachnoid blood may have a larger component coming from blood, and this may dilute the connection between CSF signals with brain metabolism per se. A seventh caveat relates to cellular origins. We performed fluorescence-activated cell sorter analysis to identify the potential cellular origin of extracellular mitochondria by MitoTracker CMXRos and each cell surface marker. But, this method only works for mitochondria contained within membranous particles. The cellular origins of naked mitochondria may be more difficult to ascertain. Eighth, all human samples underwent freeze-thaw. Although we found that JC1 values after freeze-thaw cycling were close to initial JC1 values ( Figure I in the online-only Data Supplement), better methods to preserve mitochondrial quality should be explored. Ninth, CSF mitochondrial measurements in patients with SAH may be influenced by age ( Figure II in the online-only Data Supplement). Optimizing age-appropriate thresholds may eventually be necessary to better assess clinical outcomes in wider cohorts of patients. In addition, other factors, such as sex [18] [19] [20] [21] and genetic background, 22 may also influence SAH outcome. Future studies should further validate CSF JC1 end points in larger and separate patient cohorts. Tenth, our data implicate that JC1 may be useful to assess brain integrity. But other exosomes presenting in CSF may be also important to confer disease pathology. [23] [24] [25] How specifically CSF mitochondrial function reflects brain pathological state remain to be fully addressed. Finally, we acknowledge that our observations only indicate a general relationship between extracellular mitochondria and underlying brain tissue integrity. Deeper studies are required to connect these CSF signals with multifactorial mechanisms of hemorrhagic brain injury [26] [27] [28] [29] [30] and perhaps fit these ideas into the broader concept of help-me signaling within the remodeling neurovascular unit.
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Conclusions
Taken together, these data demonstrate that extracellular mitochondria are altered in the CSF after SAH. Perhaps, most importantly, this proof-of-concept study suggests that this may not just be an experimental phenomenon; extracellular mitochondria are indeed detectable in humans, and these measurements may be functionally correlated with patient outcomes after SAH. Existing efforts to find biomarkers for brain damage typically involve intracellular and membrane proteins. 32, 33 This study suggests that extracellular mitochondria may represent a potentially new class of signals worth pursuing. The JC1 assay is relatively fast and easy to use, so these measurements may be potentially applicable at the patient bedside. Further studies are warranted to investigate this idea and assess its applicability for a wider range of central nervous system disorders. A, Functional mitochondria in cerebrospinal fluid (CSF) was labeled by MitoTracker Red CMXRox (100 nmol/L). Each cell type marker, such as vWF-FITC (von Willebrand factor-fluorescein; endothelial cell), GLAST-APC (glutamate aspartate transporter-allophycocyanin; astrocyte), CD45-FITC (microglia/macrophage), or CD41/CD61-FITC, (platelet) was coincubated with CSF. Of MitoTracker-positive events in fluorescence-activated cell sorter (FACS), positive population for each cell type marker was identified. B, FACS analysis showed that SAH subjects with good outcome at 3 months have higher percentage of GLAST+mitochondria in CSF. C, There were no differences in percentage of vWF+, CD45+, and CD41/CD61+ events between good and poor outcome groups. n.s. indicates nonsignificant.
